Skip to content

Moxibustion for cancer-related fatigue: a randomized controlled trial

Moxibustion for cancer-related fatigue: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16007798
Enrollment
Unknown
Registered
2016-01-18
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

moxibustion group:moxibustion on acupoint CV4 and ST36
nursing education group:routined nursing education and psychological counselling

Sponsors

Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Primary liver cancer patients diagnosed and verified by clinical,iconography and experimental evidence; 2. Diagnosis criteria are based on International Classification of Diseases-10; 3. BFI scores graded equal or greater than 4 and age ranging from 18 to 80; 4. had no use of any kind of traditional Chinese medicine within one week; 5. Sign informed consent; 6. estimated survival time more than one month.

Exclusion criteria

Exclusion criteria: 1. enrolled in other clinical trial; 2. leukocytopenia(WBC< 3.0*10^9/l)and low platelet count(PLT< 30*10^9/l); 3. local skin broken or with scar, ulcer or esthesiodermia; 4. Patients with high fever, convulsion,extreme tiredness, emotional instability, hyperhidrosis or drunkenness are excluded; 5. had liver and kidney function compromised or cardiovascular diseases or mental disorders.

Design outcomes

Primary

MeasureTime frame
Brief fatigue inventory;safety evaluation;

Secondary

MeasureTime frame
Anderson synptom inventory;

Countries

China

Contacts

Public ContactZHOU Qinhui
jcimzqh@163.com+86 13816319676

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026